Conference Coverage
Conference Coverage
Physicians question the future of TNF inhibitors for psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of...
Conference Coverage
Psoriasis comorbidities: Biologics may help
SEATTLE – Better mental health, cardiovascular disease outcomes linked to treatment with biologics.
Conference Coverage
Systemic psoriasis treatments less often prescribed in elderly with psoriasis, despite comparable response rates
MILAN – There was an “imbalance” in the types of medications prescribed for older and younger patients in the registry, with biologics used more...
Conference Coverage
TNF inhibitor–induced psoriasis in IBD patients a consideration
WASHINGTON –This is a paradoxical reaction, which can happen “weeks to years after starting a TNF blocker”.
Conference Coverage
Immunomodulators for pediatric skin diseases
WASHINGTON – Pediatric dermatologist A. Yasmine Kirkorian, MD, provides clinical pearls and practical considerations on the use of...
Conference Coverage
Ixekizumab psoriasis outcomes, sliced and diced
WAIKOLOA, HAWAII – The jaw-dropping NNT to achieve complete skin clearance: 2.6 patients.
Conference Coverage
What’s new with adalimumab? Plenty
WAIKOLOA, HAWAII – New information includes reassuring new long-term, real-world safety data, plus a simple early predictor of PASI 75 response....
Conference Coverage
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week...
Conference Coverage
Comorbidities may cut effectiveness of psoriasis biologics
PARIS – In the PSO-BIO-REAL study, PASI 100 rate dropped as the number of comorbidities rose.
Conference Coverage
Brodalumab raced past ustekinumab to PASI 100
PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.